SCHEMBL19852497

SCHEMBL19852497

CC(C)(C)OC(=O)N1CCC2(CC1)Cc1ccccc1C(=O)O2

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.53
GPR119 Q8TDV5 4/20 0.46
ADRA1D P25100 1/20 0.45
ADRA1A P35348 1/20 0.45
ADRA1B P35368 1/20 0.45
CHRM2 P08172 1/20 0.44
CHRM4 P08173 1/20 0.44
CHRM1 P11229 1/20 0.44
CHRM3 P20309 1/20 0.44
MAPK1 P28482 1/20 0.44
POLB P06746 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
EPHX2 P34913 2/20 0.42
EPHX1 P07099 1/20 0.42
SCN5A Q14524 1/20 0.42
TSHR P16473 2/20 0.42
ALOX15 P16050 1/20 0.42
ATM Q13315 1/20 0.42
PDK2 Q15119 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30109297 0.85 NR1H2 (0.50) HRH3GPR119ATMKMT2A
SCHEMBL20602922 0.85 GPR119 (0.42) HRH3GPR119CHRM2CHRM4CHRM1
SCHEMBL30109281 0.85 GPR119 (0.42) HRH3GPR119CHRM2CHRM4CHRM1
SCHEMBL20602904 0.85 NR1H2 (0.50) HRH3GPR119ATMKMT2A
SCHEMBL17848653 0.85 GPR119 (0.54) HRH3GPR119MAPK1EPHX2EPHX1
SCHEMBL31094899 0.85 GPR119 (0.54) HRH3GPR119MAPK1EPHX2EPHX1
SCHEMBL467280 0.83 ATM (0.56) HRH3GPR119L3MBTL1EPHX2EPHX1
SCHEMBL3702583 0.83 ATM (0.56) HRH3GPR119L3MBTL1EPHX2EPHX1
SCHEMBL20602910 0.82 ALDH1A1 (0.49) HRH3GPR119ATMKMT2A
SCHEMBL30109369 0.82 ALDH1A1 (0.49) HRH3GPR119ATMKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11186564-B2 Dual NAV1.2/5HT2a inhibitors for treating CNS disorders SUNOVION PHARMACEUTICALS INC. (US) 2021-11-30 US disclosed
US-20190194163-A1 DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS SUNOVION PHARMACEUTICALS INC. (US) 2019-06-27 US disclosed
WO-2018026371-A1 DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS SUNOVION PHARMACEUTICALS INC. (US) 2018-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190194163-A1 DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS SCN2A, HTR2A, HTR2C HRH3 2732/4885GPR119 1545/4885ADRA1D 250/4885
US-11186564-B2 Dual NAV1.2/5HT2a inhibitors for treating CNS disorders SCN2A, HTR2A, HTR2C HRH3 2732/4885GPR119 1545/4885ADRA1D 250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.